PLX
AMEX
$2.41
Protalix BioTherapeutics Inc (PLX)
Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in Israel, Brazil, the rest of Latin America and internationally. The company is headquartered in Karmiel, Israel.
Sector:
Healthcare
Industry:
Biotechnology
Target: $11 (+356.43%)
Market Cap
$186M
Profit Margin
54.3%
P/E Ratio
10.89
Free Cash Flow Yield
6.99%
Price Chart
Valuation
Market Cap$186M
P/E10.89
Forward P/E12.21
P/S2.44
P/B2.86
Profitability
Total Revenue (TTM)$76M
Gross Profit (TTM)$35M
EBITDA$21M
Profit Margin54.3%
Operating Margin62.7%
EPS$0.21
Financial Health
Free Cash Flow Yield6.99%
Growth & Risk
Revenue 5Y CAGR+7.76%
Beta (5Y)0.81
Sharpe Ratio1.01